# India RNA-based Therapeutics Market > India RNA-Based Therapeutics Market Research Report: Size, Share, Trend Analysis By Technology (RNA Interference, Antisense Oligonucleotides, mRNA Therapeutics, CRISPR Technology), By Applications (Oncology, Infectious Diseases, Genetic Disorders, Cardiovascular Diseases), By End Use (Pharmaceutical Companies, Research Institutions, Contract Research Organizations) and By Delivery Method (Liposomes, Nanoparticles, Viral Vectors, Electroporation) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 6.1% - **2024:** $ 732.7 Million - **2025:** $ 777.39 Million - **2035:** $ 1,405.6 Million - **Key Players:** Moderna (US), BioNTech (DE), Alnylam Pharmaceuticals (US), Ionis Pharmaceuticals (US), Sangamo Therapeutics (US), CureVac (DE), Arcturus Therapeutics (US), Translate Bio (US) **Report ID:** MRFR/Pharma/50896-HCR · **Pages:** 200 · **Author:** Nidhi Mandole & Garvit Vyas · **Last Updated:** August 24, 2026 **URL:** https://www.marketresearchfuture.com/reports/india-rna-based-therapeutics-market-52655 --- ## Market Summary ## **India RNA-Based Therapeutics Market Overview** As per MRFR analysis, the India RNA-Based Therapeutics Market Size was estimated at 385 (USD Million) in 2023. The India RNA-Based Therapeutics Market Industry is expected to grow from 524(USD Million) in 2024 to 1,854 (USD Million) by 2035.The India RNA-Based Therapeutics Market CAGR (growth rate) is expected to be around 12.173% during the forecast period (2025 - 2035). ### **Key India RNA-Based Therapeutics Market Trends Highlighted** The India RNA-Based Therapeutics Market is experiencing significant growth driven by various key market drivers, including the increasing prevalence of genetic disorders and infectious diseases. The rise in healthcare spending by both public and private sectors enhances the capacity for RNA-based research and development. Government initiatives, such as the Biotechnology Industry Research Assistance Council (BIRAC), promote innovation in biotechnology, underscoring India's commitment to advancing RNA therapies. Moreover, collaborations between academic institutions and biopharmaceutical companies are gaining momentum, leading to enhanced R&D capabilities in RNA therapeutics. Opportunities to be explored in the RNA-based therapeutics space include the burgeoning interest in personalized medicine and the development of advanced vaccine technologies. India’s rich biodiversity also offers a unique opportunity for discovery and development of novel RNA-based treatments. Furthermore, the ongoing focus on improving healthcare infrastructure, particularly post-pandemic, opens avenues for greater adoption of RNA therapies in disease management and prevention. Trends in recent times emphasize the rising adoption of messenger RNA (mRNA) technology, particularly in vaccine development, spotlighting India's role in global health initiatives. Collaborations with global pharmaceutical companies and local startups are fostering a vibrant ecosystem for RNA therapeutics innovation. The government’s support for biotechnology start-ups and emphasis on clinical trials is further accelerating the progress in RNA therapeutic solutions. As regulatory pathways become more streamlined, India is poised to play a significant role in the global RNA therapeutics landscape, making it an attractive hub for investment and innovation in this field. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **India RNA-Based Therapeutics Market Drivers** #### **Increasing Prevalence of Genetic Disorders** The incidence of genetic disorders has been on the rise in India, attributed to both lifestyle changes and environmental factors. According to the Indian Council of Medical Research, approximately 6-8% of the population is affected by genetic disorders, indicating a significant treatment gap. This growing number of patients suffering from conditions such as cystic fibrosis and muscular dystrophy drives the demand for RNA-based therapeutics. Organizations like the All India Institute of Medical Sciences are actively engaged in Research and Development, working on novel RNA therapies to combat these disorders. The increasing awareness among healthcare providers and patients about genetic disorders enhances the growth prospects of the India RNA-Based Therapeutics Market Industry. #### **Government Initiatives and Funding** The Indian Government has intensified its focus on bio-pharmaceutical advancements through initiatives like the 'Make in India' campaign, aimed at boosting domestic manufacturing of bio-pharmaceutical products, including therapeutics based on RNA technology. The Department of Biotechnology has increased the budget allocation for biotechnology research, which is projected to provide significant funding opportunities for innovative RNA-based projects. Such investment indicates strong support that might at least double the yearly growth rate of the India RNA-Based Therapeutics Market Industry. Furthermore underlining the sector's expansion, partnerships with reputable companies like the Biotechnology Industry Research Assistance Council inspire the creation of RNA treatments. #### **Advancements in Delivery Mechanisms** The discovery of advanced and efficient delivery mechanisms for RNA therapeutics has played a critical role in market expansion. Innovations, such as lipid nanoparticles and viral vectors, have notably improved the delivery of RNA therapies into target cells. Research institutions like the Indian Institute of Technology are conducting pioneering studies on these mechanisms, contributing to the increase in efficacy and patient compliance. The positive outcomes from these studies indicate that improved delivery systems are key facilitators for the uptake of RNA-based therapeutics, hence propelling the India RNA-Based Therapeutics Market Industry. ### **India RNA-Based Therapeutics Market Segment Insights** #### **RNA-Based Therapeutics Market Technology Insights** The India RNA-Based Therapeutics Market, particularly within the Technology segment, is witnessing significant advancements and innovations that are shaping the future of healthcare in the region. This segment encompasses various critical technologies, including RNA Interference, Antisense Oligonucleotides, mRNA Therapeutics, and CRISPR Technology, each playing a vital role in the development of novel therapeutic approaches. RNA Interference has emerged as a powerful mechanism for gene silencing, which enables the targeted treatment of diseases by modulating gene expression. This method is particularly effective in conditions such as cancer and genetic disorders, making it a focus area for research and development in India. Antisense Oligonucleotides represent another essential aspect of this market, as they allow for the specific alteration of mRNA function, thereby enabling the treatment of a variety of illnesses including rare genetic diseases, showcasing their significant therapeutic potential within the Indian healthcare landscape. mRNA Therapeutics have gained substantial attention, especially in light of recent global health challenges, demonstrating efficacy in vaccines and potential applications across numerous therapeutic areas. This technology is pivotal for the Indian market, highlighting the importance of swift and adaptable therapeutic development in response to emerging infectious diseases. Additionally, CRISPR Technology is revolutionizing the way genetic diseases are treated, providing unparalleled precision in gene editing. Its potential applications in agricultural biotechnology and medicine offer exciting prospects for India, which is focusing on enhancing healthcare and agricultural outcomes through innovative technologies. The synergy among these technologies not only sparks advancements in health solutions but also contributes to India’s position as a growing hub for biotechnology research and innovation. As the landscape continues to evolve, these technologies are set to dominate the India RNA-Based Therapeutics Market, driven by investment in research, increasing demand for advanced therapies, and supportive government initiatives aimed at fostering growth within the biotechnology sector, ultimately aiming to improve patient outcomes and public health across the nation. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review #### **RNA-Based Therapeutics Market Application Insights** The Application segment of the India RNA-Based Therapeutics Market plays a critical role in addressing various health challenges by focusing on several key areas, including Oncology, Infectious Diseases, Genetic Disorders, and Cardiovascular Diseases. This segment is characterized by the growing interest in RNA-based therapies as effective treatments for cancer, which has seen a surge in research and development due to rising cancer incidences in the country. Infectious Diseases have also gained attention, particularly in light of recent global health crises, leading to an accelerated push towards RNA vaccines and therapeutics that can be rapidly developed and deployed. Genetic Disorders represent another significant area, with advancements in gene editing technologies highlighting the potential for RNA-based treatments to offer solutions for hereditary conditions. Additionally, Cardiovascular Diseases remain a leading cause of mortality in India. The focus on developing RNA therapeutics in this segment offers promising avenues for innovative treatment options. As the healthcare system continues to evolve, the demand for advanced treatment modalities across these applications is expected to grow, driven by increasing public awareness, government initiatives, and ongoing technological advancements in RNA research and production. #### **RNA-Based Therapeutics Market End Use Insights** The India RNA-Based Therapeutics Market showcases significant engagement from various end users, prominently including Pharmaceutical Companies, Research Institutions, and Contract Research Organizations. Pharmaceutical Companies play a crucial role, focusing on the development and commercialization of RNA-based drugs, indicated for their potential in treating complex diseases such as cancer and genetic disorders, thus significantly driving innovation in therapeutics. Research Institutions contribute tremendously by advancing foundational studies and clinical trials that underscore the therapeutic applications of RNA technologies, positioning India as a hub for cutting-edge research. Meanwhile, Contract Research Organizations offer essential support by providing specialized services in drug development processes, ensuring that pharmaceutical companies can leverage external expertise and resources to expedite market entry. Collectively, these segments are aimed at tapping into the growing demand for RNA-based therapies in India, fueled by increasing investments in biotechnology and a strong regulatory push from the Indian government to foster health innovation. The synergy among these end users not only enhances product development timelines but also contributes to improving patient outcomes, thus laying a solid foundation for market expansion in the years to come. #### **RNA-Based Therapeutics Market Delivery Method Insights** The Delivery Method segment of the India RNA-Based Therapeutics Market is essential for the effective translation of RNA-based therapies from research into clinical applications. Various methods, such as Liposomes, Nanoparticles, Viral Vectors, and Electroporation, play crucial roles in determining the efficacy and safety of RNA therapeutics. Liposomes are significant as they enhance cellular uptake and provide a protective encapsulation for RNA molecules. Nanoparticles facilitate improved targeting and controlled release of therapeutics, promoting precise delivery to target cells. Viral Vectors serve as powerful tools for gene delivery, allowing high efficiency in transferring RNA to the desired cells, which is particularly important for gene therapies. Electroporation is also notable; it employs electrical fields to increase cell permeability, thereby also facilitating the introduction of RNA into cells effectively. The increasing investments in Research and Development, coupled with a supportive regulatory environment in India, further bolster the growth of innovative delivery methods within the market, driving advancements and expanding treatment options in the RNA therapeutics landscape. ### **India RNA-Based Therapeutics Market Key Players and Competitive Insights** The India [RNA-Based Therapeutics Market](../../../reports/rna-based-therapeutics-market-19244) has witnessed significant growth in recent years, driven by advancements in biotechnology and increasing investments in research and development. The competitive insights of this market reveal a landscape characterized by innovation, technology-driven approaches, and a focus on addressing unmet medical needs. Key players in the field are actively engaged in developing novel RNA-based therapies, which have emerged as promising options for various diseases, including genetic disorders, cancers, and viral infections. The market is evolving rapidly due to collaborations between pharmaceutical companies and research institutions, alongside a rise in awareness about the potential of RNA-based treatments. These dynamics have prompted companies to strategically position themselves to capitalize on market opportunities by enhancing their product portfolios and exploring new therapeutic areas. Wockhardt has established a notable presence in the India RNA-Based Therapeutics Market, leveraging its extensive expertise in bio-pharmaceuticals and a robust research infrastructure. The company's strengths lie in its commitment to quality and innovation, which have enabled it to develop a range of RNA-based products that cater to emerging therapeutic needs. With a focus on advancing biotechnology capabilities, Wockhardt is actively involved in developing solutions that address significant health challenges in India. Its strategic initiatives, including collaborations and partnerships with academic institutions, enhance its research capabilities, allowing for the efficient development of RNA therapies. The company’s ability to navigate regulatory landscapes and maintain high manufacturing standards further strengthens its position in the competitive market. Bharat Biotech is a key player in the India RNA-Based Therapeutics Market, known for its significant contributions to vaccine innovation and development. The company has been at the forefront of addressing public health concerns, particularly during disease outbreaks. Bharat Biotech's strengths include a strong focus on research and development, which has led to the introduction of numerous key products and services in the RNA therapeutic domain. The company has made strategic investments to enhance its manufacturing capabilities and has actively pursued partnerships and collaborations to expand its product offerings. Recent mergers and acquisitions have further solidified Bharat Biotech's market presence, enabling it to diversify its portfolio and leverage synergies that enhance its position within the RNA therapeutics landscape in India. Through its commitment to innovation and public health, Bharat Biotech plays a pivotal role in shaping the future of RNA-based therapies in the region. ### **Key Companies in the India RNA-Based Therapeutics Market Include** ### **India RNA-Based Therapeutics Market Industry Developments** The India RNA-Based Therapeutics Market has witnessed notable developments recently, with companies like Wockhardt, Bharat Biotech, and GSK actively participating in advancing RNA technology for various therapeutic applications. In October 2023, Bharat Biotech announced successful preclinical studies for its RNA vaccine targeting respiratory diseases, highlighting a significant investment in Research and Development. Furthermore, in September 2023, Moderna entered a strategic collaboration with Indian biotech firms to bolster its mRNA vaccine production capabilities in India, reflecting the growing inclination towards local vaccine manufacturing. Noteworthy financial growth has been reported in the RNA therapeutics sector, with Pfizer and Roche increasing their investments to enhance mRNA-based platforms, contributing to market valuation and expansion. Additionally, in March 2022, Novartis acquired a small biotech company specializing in RNA technology, reinforcing its commitment to this sector in India. The Indian government has been supportive of RNA innovations through funding and policy initiatives, aiming to position the country as a leader in biotechnology and therapeutics. Overall, the RNA-based therapeutics landscape in India is evolving rapidly, driven by strategic collaborations and government backing aimed at fostering innovation and meeting healthcare demands. ### **India RNA-Based Therapeutics Market Segmentation Insights** #### **RNA-Based Therapeutics Market Technology Outlook** #### **RNA-Based Therapeutics Market Application Outlook** #### **RNA-Based Therapeutics Market End Use Outlook** #### **RNA-Based Therapeutics Market Delivery Method Outlook** ## Market Drivers ### Advancements in Biotechnology Technological advancements in biotechnology are propelling the RNA-based therapeutics market forward in India. Innovations in RNA delivery systems, such as lipid nanoparticles and viral vectors, enhance the efficacy of RNA therapies. These advancements facilitate the development of novel therapeutics that can target specific diseases more effectively. The Indian biotechnology sector has witnessed substantial growth, with investments reaching approximately $11 billion in 2025. This influx of capital is likely to foster collaboration between academic institutions and biotech firms, further driving research and development in RNA-based treatments. Consequently, the rna based-therapeutics market is expected to benefit from these technological breakthroughs, leading to a wider array of therapeutic options for patients. ### Increasing Government Initiatives Government initiatives aimed at promoting biotechnology and healthcare innovation are significantly impacting the RNA-based therapeutics market. The Indian government has launched various programs to support research and development in the life sciences sector, including the Biotechnology Industry Research Assistance Council (BIRAC). These initiatives provide funding and resources to startups and established companies working on RNA therapies. Furthermore, the government's focus on improving healthcare access and affordability is likely to create a conducive environment for the growth of the rna based-therapeutics market. With an expected increase in public and private partnerships, the market could see a surge in the development of RNA-based solutions, potentially reaching a market size of $2 billion by 2030. ### Rising Demand for Targeted Therapies The shift towards personalized medicine is driving the demand for targeted therapies in the RNA-based therapeutics market. Patients and healthcare providers are increasingly seeking treatments that are tailored to individual genetic profiles. RNA-based therapies, which can be designed to target specific genetic mutations, align well with this trend. In India, the market for personalized medicine is projected to grow at a CAGR of 20% over the next five years. This growth is indicative of a broader acceptance of innovative treatment modalities that promise better efficacy and reduced side effects. As healthcare systems evolve, the rna based-therapeutics market is likely to expand in response to this rising demand for precision medicine. ### Growing Prevalence of Genetic Disorders The rising incidence of genetic disorders in India is a crucial driver for the RNA-based therapeutics market. With an estimated 6-8 million people affected by rare genetic diseases, the demand for innovative treatment options is increasing. RNA-based therapies offer targeted approaches to address these conditions, potentially improving patient outcomes. The Indian government has recognized the need for advanced healthcare solutions, leading to increased funding for research in this area. As a result, the rna based-therapeutics market is likely to expand, with a projected growth rate of around 15% annually over the next five years. This trend indicates a significant opportunity for companies specializing in RNA technology to develop effective treatments for genetic disorders. ### Collaboration Between Academia and Industry The collaboration between academic institutions and the biotechnology industry is fostering innovation in the RNA-based therapeutics market. Indian universities and research centers are increasingly partnering with biotech firms to advance RNA research and development. These collaborations often lead to the commercialization of novel therapies, bridging the gap between laboratory discoveries and clinical applications. With the Indian biotechnology sector projected to grow at a rate of 14% annually, such partnerships are essential for driving the rna based-therapeutics market forward. By leveraging academic expertise and industry resources, these collaborations may accelerate the development of RNA-based treatments, ultimately benefiting patients and healthcare providers alike. ## Future Outlook The [RNA Based Therapeutics Market](https://www.marketresearchfuture.com/reports/rna-based-therapeutics-market-19244) is projected to grow at a 6.1% CAGR from 2025 to 2035, driven by advancements in gene editing, increased investment, and rising demand for personalized medicine. **New opportunities:** - Development of RNA delivery systems for targeted therapies. Partnerships with biotech firms for innovative RNA-based solutions. Expansion into emerging markets with tailored RNA therapies. By 2035, the RNA-based therapeutics market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Technology: mRNA Therapeutics (Largest) vs. CRISPR Technology (Fastest-Growing) In the India RNA-based therapeutics market, the distribution of market share among key technology segments reveals that mRNA therapeutics take the lead, demonstrating significant traction and acceptance in therapeutic applications. Meanwhile, RNA interference and antisense oligonucleotides also hold substantial portions, indicating a diverse landscape that underscores different technological advancements. Looking at growth trends, mRNA therapeutics are benefiting from increased investments and clinical trials, establishing their presence as the predominant choice for modern therapies. In contrast, CRISPR technology is emerging at an unprecedented rate, driven by advancements in gene editing capabilities and rising funding, making it the fastest-growing segment as researchers explore its versatile applications in various diseases. mRNA Therapeutics (Dominant) vs. CRISPR Technology (Emerging) mRNA therapeutics represent a dominant force within the segment, largely due to their proven efficacy and versatility in targeting a wide array of diseases, notably infectious diseases and cancers. Their successful European and American trials enhance their credibility in the Indian market. Conversely, CRISPR technology, while still emerging, showcases immense potential for gene editing and modification, garnering attention from biopharmaceutical companies. Its rapid evolution is fueled by innovative research and strategic collaborations, enabling its application across genetic disorders and agricultural enhancements, thus making a significant impact on future therapeutic developments. ### By Application: Oncology (Largest) vs. Infectious Diseases (Fastest-Growing) In the application segment of the India RNA-based therapeutics market, Oncology holds the largest share, reflecting the significant demand for targeted therapies in cancer treatment. This segment has seen steady growth due to an increase in cancer prevalence and the ongoing shift towards personalized medicine, which emphasizes the need for advanced therapeutic solutions. On the other hand, the Infectious Diseases segment is identified as the fastest-growing area within the market. This growth is fueled by the rising incidence of infectious diseases and the urgent need for innovative treatment options, especially in the wake of recent global health crises. The pressing need for effective rna-based therapies is pushing research and development in this sector to new heights. Oncology (Dominant) vs. Genetic Disorders (Emerging) Oncology is the dominant segment in the application category, driven by increasing investments in cancer research and the development of novel rna-based treatments. The focus on precision medicine is paramount, enabling more effective targeting of cancer cells while minimizing damage to healthy tissue. In contrast, Genetic Disorders represent an emerging segment, gaining traction as advancements in gene therapy and rna technology create new therapeutic avenues. The rising awareness and diagnosis of genetic disorders are expected to drive further growth, as stakeholders recognize the potential of rna therapeutics in addressing these conditions. Both segments reflect a robust pipeline of innovations tailored to meet specific patient needs. ### By End Use: Pharmaceutical Companies (Largest) vs. Research Institutions (Fastest-Growing) The market share distribution in the India RNA-based therapeutics market reveals that Pharmaceutical Companies hold a significant portion, indicating their dominance in utilizing RNA therapies for drug development and innovation. In contrast, Research Institutions, while smaller in market share, are increasingly gaining attention as they drive critical research initiatives and clinical trials aimed at exploring novel RNA-based therapies and their applications. Growth trends within this segment highlight the robust expansion of Research Institutions driven by increasing funding for innovative research and the growing demand for personalized medicine, which fosters collaboration with Pharmaceutical Companies. The drive towards developing groundbreaking RNA therapies is being primarily fueled by advancements in genetic research and partnerships between academia and industry, propelling Research Institutions to play a pivotal role in the future of the market. Pharmaceutical Companies: Dominant vs. Research Institutions: Emerging Pharmaceutical Companies represent the dominant player in the India rna based-therapeutics market due to their substantial investments in research and development, regulatory expertise, and established distribution networks. They leverage RNA technology to enhance drug efficacy and safety profiles. On the other hand, Research Institutions are emerging as key contributors by fostering innovation through cutting-edge research and collaboration with industry stakeholders. While Pharmaceutical Companies focus on commercial applications, Research Institutions emphasize discovery and validation of new RNA therapeutics, often acting as catalysts for the next wave of advancements. This dynamic interplay between the two sectors lays the groundwork for future growth and innovation in the market. ### By Delivery Method: Viral Vectors (Largest) vs. Liposomes (Fastest-Growing) The market share distribution among the delivery methods highlights the prominence of viral vectors, which are currently the largest segment in the India RNA-based therapeutics market. This segment's established presence and effectiveness in gene delivery provide a strong competitive advantage. In contrast, liposomes are gaining traction, marked by their rapid growth due to their favorable properties, including biocompatibility and versatility in drug formulation. Their increasing application in therapeutic delivery is indicative of a shift towards more advanced formulations. The growth trends in the delivery method segment are driven by technological advancements and rising investments in research and development. The shift towards personalized medicine and the need for targeted therapies are additional catalysts propelling the demand for innovative delivery systems. Viral vectors will continue to dominate due to their effectiveness, while liposomes are expected to see the fastest growth trajectory, reflecting a market that is increasingly responding to the complexities of modern therapeutics. Viral Vectors (Dominant) vs. Liposomes (Emerging) Viral vectors, recognized for their high efficiency in gene transfer, are currently dominating the market due to their widespread application in therapeutic approaches, including cancer treatment and genetic disorders. Their ability to deliver genetic material effectively into target cells positions them as a go-to choice for many researchers and practitioners. On the other hand, liposomes represent an emerging trend in the delivery method space. Their unique structure allows for improved drug solubility and controlled release, making them highly appealing in therapeutic contexts. As the push for nanomedicine amplifies, liposomes are set to rise sharply in adoption, offering substantial promise for future innovations in drug delivery systems within the India rna based-therapeutics market. ## Competitive Benchmarking The rna based-therapeutics market is currently characterized by a dynamic competitive landscape, driven by innovation, strategic partnerships, and regional expansion. Key players such as Moderna (US), BioNTech (DE), and Alnylam Pharmaceuticals (US) are at the forefront, each adopting distinct strategies to enhance their market presence. Moderna (US) continues to focus on mRNA technology, emphasizing its applications beyond infectious diseases, while BioNTech (DE) is leveraging its expertise in personalized medicine to develop tailored therapies. Alnylam Pharmaceuticals (US) is concentrating on RNA interference (RNAi) therapeutics, aiming to address rare genetic disorders, which positions it uniquely within the market. Collectively, these strategies contribute to a competitive environment that is increasingly innovation-driven, with companies vying for leadership through technological advancements and strategic collaborations.In terms of business tactics, companies are increasingly localizing manufacturing to enhance supply chain resilience and reduce operational costs. This approach is particularly relevant in the context of the Indian market, where logistical challenges can impact product availability. The market structure appears moderately fragmented, with several players competing for market share, yet the influence of major companies remains substantial. Their collective actions shape the market dynamics, as they invest in research and development to bring novel therapies to fruition. In October Moderna (US) announced a partnership with a leading Indian biotech firm to establish a local manufacturing facility for mRNA-based therapeutics. This strategic move is expected to enhance supply chain efficiency and reduce costs, while also facilitating quicker access to innovative treatments for the Indian population. Such initiatives reflect a growing trend among companies to localize operations in response to regional market demands. In September BioNTech (DE) expanded its collaboration with a prominent Indian research institution to accelerate the development of personalized cancer therapies. This partnership underscores BioNTech's commitment to harnessing local expertise and resources, which may significantly enhance its research capabilities and expedite the delivery of cutting-edge treatments to patients in India. The strategic importance of this collaboration lies in its potential to foster innovation and improve patient outcomes in oncology. In August Alnylam Pharmaceuticals (US) launched a new RNAi therapeutic targeting a rare genetic disorder, following successful clinical trials in India. This launch not only demonstrates Alnylam's commitment to addressing unmet medical needs but also highlights the growing acceptance and integration of RNA-based therapies within the Indian healthcare system. The strategic significance of this event is profound, as it positions Alnylam as a leader in the niche market of RNAi therapeutics, potentially paving the way for future innovations. As of November the competitive trends in the rna based-therapeutics market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) in research and development processes. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in driving innovation and enhancing operational efficiencies. Looking ahead, competitive differentiation is likely to evolve, shifting from traditional price-based competition to a focus on technological innovation, supply chain reliability, and the ability to deliver personalized therapies. This transition may redefine the competitive landscape, as companies that prioritize these aspects are poised to gain a significant advantage. ## Recent News & Developments The India RNA-Based Therapeutics Market has witnessed notable developments recently, with companies like Wockhardt, Bharat Biotech, and GSK actively participating in advancing RNA technology for various therapeutic applications. In October 2023, Bharat Biotech announced successful preclinical studies for its RNA vaccine targeting respiratory diseases, highlighting a significant investment in Research and Development. Furthermore, in September 2023, Moderna entered a strategic collaboration with Indian biotech firms to bolster its mRNA vaccine production capabilities in India, reflecting the growing inclination towards local vaccine manufacturing. Noteworthy financial growth has been reported in the RNA therapeutics sector, with Pfizer and Roche increasing their investments to enhance mRNA-based platforms, contributing to market valuation and expansion. Additionally, in March 2022, Novartis acquired a small biotech company specializing in RNA technology, reinforcing its commitment to this sector in India. The Indian government has been supportive of RNA innovations through funding and policy initiatives, aiming to position the country as a leader in biotechnology and therapeutics. Overall, the RNA-based therapeutics landscape in India is evolving rapidly, driven by strategic collaborations and government backing aimed at fostering innovation and meeting healthcare demands. ## Report Scope | MARKET SIZE 2024 | 732.7(USD Million) | | --- | --- | | MARKET SIZE 2025 | 777.39(USD Million) | | MARKET SIZE 2035 | 1405.6(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.1% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Moderna (US), BioNTech (DE), Alnylam Pharmaceuticals (US), Ionis Pharmaceuticals (US), Sangamo Therapeutics (US), CureVac (DE), Arcturus Therapeutics (US), Translate Bio (US) | | Segments Covered | Technology, Application, End Use, Delivery Method | | Key Market Opportunities | Advancements in RNA delivery systems enhance therapeutic efficacy in the rna based-therapeutics market. | | Key Market Dynamics | Growing investment in Research and Development drives innovation in the RNA based-therapeutics market. | | Countries Covered | India | ## Frequently Asked Questions **Q: What is the current valuation of the RNA based-therapeutics market in India?** A: The overall market valuation was $732.7 Million in 2024. **Q: What is the projected market size for RNA based-therapeutics in India by 2035?** A: The projected valuation for 2035 is $1405.6 Million. **Q: What is the expected CAGR for the RNA based-therapeutics market in India during the forecast period 2025 - 2035?** A: The expected CAGR during this period is 6.1%. **Q: Which companies are the key players in the RNA based-therapeutics market in India?** A: Key players include Moderna, BioNTech, Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Sangamo Therapeutics, CureVac, Arcturus Therapeutics, and Translate Bio. **Q: What are the main technology segments in the RNA based-therapeutics market?** A: Main technology segments include RNA Interference, Antisense Oligonucleotides, mRNA Therapeutics, and CRISPR Technology. **Q: How did the mRNA Therapeutics segment perform in 2024?** A: The mRNA Therapeutics segment was valued at $300 Million in 2024 and is expected to grow significantly. **Q: What applications are driving the RNA based-therapeutics market in India?** A: Key applications include Oncology, Infectious Diseases, Genetic Disorders, and Cardiovascular Diseases. **Q: What was the valuation of the Oncology application segment in 2024?** A: The Oncology application segment was valued at $200 Million in 2024. **Q: What delivery methods are utilized in the RNA based-therapeutics market?** A: Delivery methods include Liposomes, Nanoparticles, Viral Vectors, and Electroporation. **Q: What is the expected growth trajectory for the Contract Research Organizations segment?** A: The Contract Research Organizations segment was valued at $232.7 Million in 2024 and is likely to expand during the forecast period. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/india-rna-based-therapeutics-market-52655*